Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
The study of two rare childhood neurodegenerative diseases leads St. Jude Children’s Research Hospital scientists to a new source of DNA damage that may play a role in a wide range of health problems, including cancer. (Peter McKinnon, PhD)
St. Jude Children's Research Hospital scientists have rewritten the job description of the protein TopBP1 after demonstrating that it guards early brain cells from DNA damage. Such damage might foreshadow later problems, including cancer. (Dr. Peter McKinnon)
For many years, St. Jude researchers have been investigating the connection between genetics and pediatric cancer. Those approaches continue to have dramatic implications for clinical care.
Switching off a key DNA repair system in the developing nervous system is linked to smaller brain size as well as problems in brain structures vital to movement, memory and emotion, according to new research led by St. Jude Children’s Research Hospital scientists.
Scientists at St. Jude have generated new models of medulloblastoma tumors by inactivating different DNA repair pathways, specifically in the brain.
St. Jude scientists have teased apart the biological details distinguishing two related neurological diseases—ataxia telangiectasia-like disease (ATLD) and Nijmegen breakage syndrome (NBS).
St. Jude scientists’ findings in ataxia telangiectasia-like disease and Nijmegen breakage syndrome offer insight into the links between brain disease and cancer vulnerability in people carrying the diseases.
St. Jude investigators have gained some of the first major insights into how certain genes known to prevent cancer also guide the nervous system's normal development before birth and during infancy by repairing DNA damage.
St. Jude investigators have discovered that the DNA repair pathway called homologous recombination (HR) works primarily during the first half of embryo development, when many cells are dividing inside the growing body.
A protein called Scythe determines which cells live and which die during the growth and development of the mammalian embryo, according to St. Jude researchers.
Proof that PUMA stalks cancer cells solves a long-standing mystery of the anti-cancer role of p53